Clinical trial · no report yet · Phase 2
NeoPACT
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
- NCT03639948 ↗
- Unknown
- University of Kansas Medical Center
- 38 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 15 | |
| Podcasts | 15 | |
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Carboplatin; Docetaxel; Pembrolizumab; Pegfilgrastim
- Arms
- Experimental: Carboplatin & Docetaxel plus Pembroluzimab · Experimental
- Enrollment
- 120
- Primary outcomes
- Pathological Complete Response (pCR) Rate
- Sponsor
- University of Kansas Medical Center with Merck Sharp & Dohme LLC
- Start
- Sep 4, 2018
- Primary completion
- Jan 27, 2022
- Results posted
- Yes
- Registry record
- NCT03639948 · updated Apr 11, 2024
Publications
linked from the registry- Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O'Dea A, Nye L, Satelli D, Crane G, Madan R, O'Neil MF, Wagner J, Larson KE, Balanoff C, Kilgore L, Phadnis MA, Godwin AK, Salgado R, Khan QJ, O'Shaughnessy J. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol. 2024 Feb 1;10(2):227-235. doi: 10.1001/jamaoncol.2023.5033. PubMed 37991778